Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.

被引：0
|
作者：
Jiang, Di Maria
Jang, Raymond Woo-Jun
Chan, Kelvin K.
Liu, Geoffrey
Amir, Eitan
Elimova, Elena
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.6619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6619
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (05) : 2949 - 2970
  • [22] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1619 - 1632
  • [23] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (08) : 1619 - 1632
  • [24] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
    Kayki-Mutlu, Gizem
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (05) : 839 - 852
  • [25] A COMPARISON OF ANTIEPILEPTIC DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION AND HEALTH CANADA
    Alsharaimy, F.
    Chong, D.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    Eguale, T.
    VALUE IN HEALTH, 2017, 20 (05) : A199 - A199
  • [26] Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Administration.
    Molto, Consolacion
    Hwang, Thomas J.
    Andres, Marta
    Borrell, Maria
    Gich Saladich, Ignasi J.
    Barnadas, Agust
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau Martorell, Ariadna
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications
    Yu, Jingjing
    Wang, Yan
    Ragueneau-Majlessi, Isabelle
    CLINICAL THERAPEUTICS, 2022, 44 (11) : 1536 - 1544
  • [28] Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical RecommendationsS
    Yu, Jingjing
    Wang, Yan
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (01) : 1 - 7
  • [29] Evaluating the clinical benefits of anti-cancer drugs approved by Food and Drug Administration for gastrointestinal neoplasms for the past two decades.
    Jamal, Fares
    Sahvan, Oudai
    Bekaii-Saab, Tanios S.
    Sonbol, Mohamad Bassam
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [30] Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
    Molto, C.
    Restrepo, A. P.
    Templeton, A. J.
    Tibau, A.
    Mittal, A.
    Tamimi, F. T.
    Gimenez, D. Malon
    Amir, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S931 - S931
12345